U.S. stock movement: Moderna plunges on October 22 amid pending cancer vaccine data and profit-taking at highs

Moderna’s Sharp Drop on October 22 – Analysis

Keywords: Cancer vaccine data pending, profit-taking at highs

On October 22, 2026, reports indicated that the complete phase III data of Moderna’s personalized cancer therapy in collaboration with Merck is expected to be released on October 24. Critical clinical results have yet to be disclosed, creating uncertainty around efficacy and subsequent commercialization prospects. Meanwhile, the share price has surged approximately 47% in the past 30 days and around 674% year-to-date. After such a substantial rally, there is profit-taking pressure ahead of the key data release, which may amplify short-term pullbacks.

(Disclaimer: This content is generated by AI technology through the synthesis of publicly available information and is for reference only. It does not constitute investment advice.)